{"id":552,"date":"2015-04-21T14:46:28","date_gmt":"2015-04-21T09:16:28","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=552"},"modified":"2025-05-05T17:39:24","modified_gmt":"2025-05-05T12:09:24","slug":"a-glimpse-of-the-anticoagulants-therapy-market-major-players","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players","title":{"rendered":"A Glimpse of the Anticoagulants Therapy Market; Major Players"},"content":{"rendered":"<blockquote>\n<p><img decoding=\"async\" class=\"  wp-image-551 alignright\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/anticoagulants.jpg\" alt=\"Anticoagulants\" width=\"293\" height=\"220\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/04\/20112006\/anticoagulants.jpg 800w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/04\/20112006\/anticoagulants-20x15.jpg 20w\" sizes=\"(max-width: 293px) 100vw, 293px\" \/><\/p>\n<p><span style=\"color: #ff0000;\">VTE therapeutics &amp;\u00a0Atrial Fibrillation market was worth USD 4 billion in 2014 and\u00a0USD 7.86 billion respectively. The\u00a0VTE therapeutic\u00a0market is\u00a0expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29% and\u00a0Atrial Fibrillation market\u00a0will reach on its peak value USD 13.28 billion by\u00a02018 \u00a0with compound annual growth rate (CAGR) of 14%, according to DelveInsight Analysis.<\/span><\/p>\n<p>\u00a0<\/p>\n<\/blockquote>\n<p><span style=\"color: #000080;\"><strong>Anticoagulants reduce blood clotting in an artery, a vein or the heart. Clots can block the blood flow to heart muscle leading to heart attack. They can also block blood flow to brain, leading to stroke. Anticoagulants are given to prevent blood from clotting or prevent existing clots from getting larger.<\/strong><\/span><\/p>\n<p>\u00a0<\/p>\n<p style=\"text-align: justify;\">Warfarin and Heparin were the only available anticoagulants since decades but now, the choice of anticoagulants is broadened by the approval of new oral anticoagulants bu U.S. Food and Drug Administration. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban. These novel oral anticoagulants are expected to replace older anticoagulants with their ease of use and favourable pharmacodynamic profiles.<\/p>\n<p style=\"text-align: justify;\"><strong>Dabigatran<\/strong> and <strong>Rivaroxaban<\/strong>\u00a0were the highest selling drugs in <strong>2014<\/strong> with the revenue generated <strong>~1800 million and ~1700 million<\/strong> respectively. Dabigatran was the first oral direct thrombin inhibitor approved by U.S. FDA and Rivaroxaban was the first oral direct coagulation factor Xa inhibitor approved by U.S. FDA. <span style=\"text-decoration: underline; color: #000000;\"><span style=\"text-decoration: underline;\">The patent for Dabigatran is going to expire soon (in 2017) thus making way for generic drug in the market<\/span><\/span><span style=\"color: #000000;\">.<\/span> Edoxaban is the newly approved (January 2015) factor Xa inhibitor for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE).<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" class=\"aligncenter  wp-image-549\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/sales-of-major-players-in-the-market.png\" alt=\"Sales of major players in the market\" width=\"467\" height=\"274\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/04\/08130319\/sales-of-major-players-in-the-market.png 581w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/04\/08130319\/sales-of-major-players-in-the-market-20x12.png 20w\" sizes=\"(max-width: 467px) 100vw, 467px\" \/><\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-550\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/sales-of-major-players-in-the-market.jpg\" alt=\"Sales of major players in the market\" width=\"442\" height=\"109\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/04\/sales-of-major-players-in-the-market.jpg 442w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/04\/sales-of-major-players-in-the-market-300x74.jpg 300w\" sizes=\"(max-width: 442px) 100vw, 442px\" \/><\/p>\n<blockquote>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\"><strong>Despite novel anticoagulants are seen as replacements for heparin and warfarin, there are some adverse hemorrhagic events reported. Absence of any approved antidotes for oral anticoagulants limit their use. Though there are 3 antidotes in clinical development which can reverse the effects in case of major bleeding. <span style=\"text-decoration: underline;\">These antidotes are 1.5 years away from being clinically available<\/span>.<\/strong><\/span><\/p>\n<\/blockquote>\n<p style=\"text-align: justify;\"><strong>Since the patient compliance increases with the orally available drugs, the companies are focusing on developing such anticoagulants. The drugs in pipeline are mostly thrombin inhibitors or Factor Xa inhibitors unlike traditionally used warfarin which was Vitamin K reductase inhibitor.<\/strong><\/p>\n<p style=\"text-align: justify;\">Anticoagulants are prescribed for number of diseases such as Heart attack, stroke, deep venous thromboembolism, pulmonary embolism, Atrial fibrillation, Unstable angina, or for the prevention of Venous thromboembolism (VTE) after major orthopedic surgery. With such a wide usage, one must be familiar with anticoagulants, their pharmacological properties, pharmacodynamics, dosing, monitoring and toxicity.<\/p>\n<p><em>Written by Rashi Aggarwal, Associate Analyst at DelveInsight<\/em><\/p>\n<h5>Report:\u00a0<strong>Anticoagulants-Competitive Landscape, Market &amp; Pipeline Analysis, Forecasted Market Size 2015-2018<\/strong><\/h5>\n<p><strong><em>Give your views in the comment section and for more information on this Report and Sample Pages mail us at info@delveinsight.com<\/em><\/strong><\/p>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>VTE therapeutics &amp;\u00a0Atrial Fibrillation market was worth USD 4 billion in 2014 and\u00a0USD 7.86 billion respectively. The\u00a0VTE therapeutic\u00a0market is\u00a0expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29% and\u00a0Atrial Fibrillation market\u00a0will reach on its peak value USD 13.28 billion by\u00a02018 \u00a0with compound annual growth rate (CAGR) of 14%, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[46,47,79,80,97,200,203,242,248,281,287,369,372,373,435,452,500,522,528,548,572,587,602,605,606],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-552","post","type-post","status-publish","format-standard","hentry","category-articles","tag-46","tag-47","tag-anticoagulants","tag-anticoagulants-competitive-landscape","tag-atrial-fibrillation","tag-dabigatran","tag-deep-venous-thromboembolism","tag-factor-xa-inhibitors","tag-forecasted-market-size-2015-2018","tag-heart-attack","tag-heparin","tag-major-players","tag-market","tag-market-pipeline-analysis","tag-oral-anticoagulants","tag-patent","tag-pulmonary-embolism","tag-rivaroxaban","tag-sales","tag-stroke","tag-thrombin-inhibitors","tag-unstable-angina","tag-vitamin-k-reductase-inhibitor","tag-vte-therapeutics","tag-warfarin","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Anticoagulants Therapy Market Size and Trends | DelveInsight<\/title>\n<meta name=\"description\" content=\"Anticoagulants are given to prevent blood from clotting. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anticoagulants Therapy Market Size and Trends | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Anticoagulants are given to prevent blood from clotting. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-21T09:16:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T12:09:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/anticoagulants.jpg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anticoagulants Therapy Market Size and Trends | DelveInsight","description":"Anticoagulants are given to prevent blood from clotting. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players","og_locale":"en_US","og_type":"article","og_title":"Anticoagulants Therapy Market Size and Trends | DelveInsight","og_description":"Anticoagulants are given to prevent blood from clotting. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban.","og_url":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-04-21T09:16:28+00:00","article_modified_time":"2025-05-05T12:09:24+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/anticoagulants.jpg","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players","url":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players","name":"Anticoagulants Therapy Market Size and Trends | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/anticoagulants.jpg","datePublished":"2015-04-21T09:16:28+00:00","dateModified":"2025-05-05T12:09:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Anticoagulants are given to prevent blood from clotting. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/a-glimpse-of-the-anticoagulants-therapy-market-major-players#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/anticoagulants.jpg","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/anticoagulants.jpg"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">2014<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">2015<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Anticoagulants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Anticoagulants-Competitive Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atrial Fibrillation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dabigatran<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">deep venous thromboembolism<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Factor Xa inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Forecasted Market Size 2015-2018<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Heart Attack<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Heparin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Major Players<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market &amp; Pipeline Analysis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oral Anticoagulants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Patent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pulmonary embolism<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rivaroxaban<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sales<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">stroke<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">thrombin inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Unstable angina<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vitamin K reductase inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">VTE therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">warfarin<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">2014<\/span>","<span class=\"advgb-post-tax-term\">2015<\/span>","<span class=\"advgb-post-tax-term\">Anticoagulants<\/span>","<span class=\"advgb-post-tax-term\">Anticoagulants-Competitive Landscape<\/span>","<span class=\"advgb-post-tax-term\">Atrial Fibrillation<\/span>","<span class=\"advgb-post-tax-term\">Dabigatran<\/span>","<span class=\"advgb-post-tax-term\">deep venous thromboembolism<\/span>","<span class=\"advgb-post-tax-term\">Factor Xa inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Forecasted Market Size 2015-2018<\/span>","<span class=\"advgb-post-tax-term\">Heart Attack<\/span>","<span class=\"advgb-post-tax-term\">Heparin<\/span>","<span class=\"advgb-post-tax-term\">Major Players<\/span>","<span class=\"advgb-post-tax-term\">Market<\/span>","<span class=\"advgb-post-tax-term\">Market &amp; Pipeline Analysis<\/span>","<span class=\"advgb-post-tax-term\">Oral Anticoagulants<\/span>","<span class=\"advgb-post-tax-term\">Patent<\/span>","<span class=\"advgb-post-tax-term\">pulmonary embolism<\/span>","<span class=\"advgb-post-tax-term\">Rivaroxaban<\/span>","<span class=\"advgb-post-tax-term\">Sales<\/span>","<span class=\"advgb-post-tax-term\">stroke<\/span>","<span class=\"advgb-post-tax-term\">thrombin inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Unstable angina<\/span>","<span class=\"advgb-post-tax-term\">Vitamin K reductase inhibitor<\/span>","<span class=\"advgb-post-tax-term\">VTE therapeutics<\/span>","<span class=\"advgb-post-tax-term\">warfarin<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Apr 21, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Apr 21, 2015 2:46 pm","modified":"Updated on May 5, 2025 5:39 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=552"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/552\/revisions"}],"predecessor-version":[{"id":31675,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/552\/revisions\/31675"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=552"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=552"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}